Single doublecortin gene therapy significantly reduces glioma tumor volume.
We employed lentivirus-based doublecortin (DCX), as a glioma suppressor gene therapy in an intracranial glioma tumor xenograft model in nude rats. Single DCX-expressing lentivirus was directly administered into the tumor on day 8 after U87 tumor cell implantation. DCX treatment significantly reduced U87 glioma tumor volume (approximately 60%) on day 14 after DCX lentivirus injection and significantly improved median survival of tumor-bearing nude rats. DCX synthesis induced neuronal markers MAP2, TUJ1, and PSA-NCAM and the glial marker glial fibrillary acidic protein (GFAP) in the implanted U87 glioma tumors. DCX synthesis induced GFAP that colocalized with tubulin in the mitotic stage, inhibited cleavage furrow during cytokinesis, and blocked mitosis in glioma cells. DCX lentivirus infection did not induce apoptosis but significantly inhibited expression of the proliferation marker Ki-67 and the blood vessel marker von-Willebrand factor (vWF). U87 and other glioma cells except for brain tumor stem cells (BTSCs) do not express neuronal markers or both neuronal and glial markers. DCX-synthesizing glioma cells express a phenotype of antiangiogenic BTSC-like cells with terminal differentiation that causes remission of glioma cells by blocking mitosis via a novel DCX/GFAP pathway. Direct local delivery of lentivirus-based DCX gene therapy is a potential differentiation-based therapeutic approach for the treatment of glioma.
Santra
Manoranjan
M
Department of Neurology, Henry Ford Hospital, Detroit, Michigan 48202, USA.
Zheng
Xuguang
X
Roberts
Cindi
C
Santra
Sutapa
S
Lu
Mei
M
Panda
Swayamprava
S
Jiang
Feng
F
Chopp
Michael
M
D000818:Animals; D001253:Astrocytes / Q000473:pathology / Q000502:physiology; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D001932:Brain Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D045744:Cell Line, Tumor; D048749:Cytokinesis / Q000502:physiology; D000089622:Doublecortin Domain Proteins; D000089662:Doublecortin Protein; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D005910:Glioma / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D016086:Lentivirus / Q000235:genetics; D008869:Microtubule-Associated Proteins / Q000235:genetics* / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D009474:Neurons / Q000473:pathology / Q000502:physiology; D009479:Neuropeptides / Q000235:genetics* / Q000627:therapeutic use*; D051381:Rats; D011923:Rats, Nude; D016896:Treatment Outcome
C000714848:Dcx protein, rat; D000089622:Doublecortin Domain Proteins; D000089662:Doublecortin Protein; D005904:Glial Fibrillary Acidic Protein; D008869:Microtubule-Associated Proteins; D009479:Neuropeptides
Cell. 1998 Jan 9;92(1):63-72
9489700
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6367-72
9600971
Cancer Res. 2008 May 15;68(10):3724-32
18483255
Nature. 2006 Dec 7;444(7120):761-5
17151667
BMC Neurosci. 2008 Feb 29;9:31
18312642
Nature. 2004 Nov 18;432(7015):396-401
15549107
J Clin Invest. 1997 Jul 1;100(1):149-57
9202067
Nat Clin Pract Neurol. 2008 Aug;4(8):427-35
18628751
Neuroscience. 2006 Oct 27;142(3):739-52
16962712
Science. 2008 Dec 19;322(5909):1811-5
19095934
Oncogene. 1997 Oct 23;15(17):2037-48
9366521
Nature. 2001 Nov 1;414(6859):105-11
11689955
Exp Neurol. 2007 Oct;207(2):357-67
17706196
Glia. 2002 Sep;39(3):193-206
12203386
Cancer Res. 2006 Dec 15;66(24):11726-35
17178868
Nat Med. 2001 Jan;7(1):33-40
11135613
Cancer Cell. 2006 May;9(5):391-403
16697959
EMBO J. 2002 Jul 15;21(14):3770-81
12110589
J Cell Biol. 1998 Nov 30;143(5):1249-58
9832553
Carcinogenesis. 2000 Jul;21(7):1271-9
10874003
Eur J Neurosci. 2007 Jun;25(12):3489-98
17610569
Neurosurg Focus. 2006 Apr 15;20(4):E27
16709033
Am J Pathol. 2005 Jun;166(6):1841-50
15920168
Cancer Res. 2003 Sep 15;63(18):5821-8
14522905
J Biol Chem. 1996 Feb 9;271(6):3311-6
8621736
Nat Rev Genet. 2003 May;4(5):346-58
12728277
Mol Cancer. 2006 Dec 02;5:67
17140455
Lab Invest. 1998 Feb;78(2):165-74
9484714
J Anat. 2007 Jan;210(1):54-65
17229283
J Neurosci. 2005 Mar 9;25(10):2637-46
15758174
Cancer Res. 2004 Oct 1;64(19):7011-21
15466194
Nat Genet. 1997 Apr;15(4):356-62
9090379
Nat Med. 2002 Sep;8(9):963-70
12161747
J Neurochem. 2009 Jan;108(1):231-45
19094064